Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer's Giotrif gains best IQWiG outcome... and worst

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim is the proud recipient of the best possible IQWiG benefit assessment outcome for lung cancer product Giotrif (afatinib). Unfortunately, the drug also received the worst possible outcome in a small subsection of patients. With the mixed bag of results, Boehringer is not celebrating yet, but this could be an important step to proving it can demonstrate clinical efficacy in one of Europe's toughest markets, which is essential for the company as it tries to compete with Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts